Director of Translational Research at the Pancreatic Cancer Research Center at Penn Medicine, Gregory Beatty, PhD, has devoted his career to understanding the idiosyncratic character of pancreatic ductal adenocarcinoma (PDA). In this engaging presentation, he describes the current strategies and evolving immunotherapies for pancreatic cancer and their potential to improve both the standards of care and the outcomes for the disease.
Dr. Beatty spoke at the Abramson Cancer Center’s Immunology and Immunotherapy for Pancreatic Cancer Symposium.
Related Links:
Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma ABCs of Cancer Immunology: What a Practicing Oncologist Needs to Know
Twitter
Dr. Beatty’s physician profile
Connect with Dr. Beatty on Doxmity
Published
September 9, 2019
Created by
BROADCASTMED